‘Brain Fogginess’ and D-Lactic Acidosis: Probiotics Are Not the Cause

Clinical and Translational Gastroenterology

Volumn 9, Issue 9, 2018, Pages

  Quigley, Eamonn M M ^a   Pot, Bruno ^b   Sanders, Mary Ellen ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c International Scientific Association for Probiotics and Prebiotics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; BACTERIAL METABOLISM; BACTERIAL OVERGROWTH; BIFIDOBACTERIUM; BLOATING; BRAIN DISEASE; BRAIN FOGGINESS; DISEASE ASSOCIATION; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LACTIC ACIDEMIA; LACTIC ACIDOSIS; LACTOBACILLUS JOHNSONII; LACTOBACILLUS PLANTARUM; LETTER; NONHUMAN; PRIORITY JOURNAL; SHORT BOWEL SYNDROME; ACIDOSIS; BRAIN; FLATULENCE;

ACIDOSIS; ACIDOSIS, LACTIC; BRAIN; FLATULENCE; HUMANS; PROBIOTICS;

EID: 85053914513     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/s41424-018-0057-9     Document Type: Letter

References (9)

1. Rao, S. S. C., Rehman, A., Yu, S. & Andino, N. M. Brain fogginess, gas and bloating: a link between SIBO, probiotics and metabolic acidosis. Clin. Transl. Gastroenterol. 9, 162 (2018).
2. Sanders, M. E., Merenstein, D. & Merrifield, C. A. Probiotics for human use. Nutr. Bull. 43, 212–225 (2018).
3. de Vries, W. & Stouthamer, A. H. Fermentation of glucose, lactose, galactose, mannitol, and xylose by bifidobacteria. J. Bacteriol. 96, 472–478 (1968).
4. Gigante, A. et al. D-Lactic acidosis 25 years after bariatric surgery due to Salmonella enteritidis. Nutrition 28, 108–111 (2012).
5. Yilmaz, B., Schibli, S., Macpherson, A. J. & Sokollik, C. D-lactic acidosis: successful suppression of D-lactate-producing Lactobacillus by probiotics. Pediatrics 142, pii: e20180337 (2018).
6. Stanciu S., De Silva A. Metabolic acidosis in short bowel syndrome: think D-lactic acid acidosis. BMJ Case Rep. 2018;pii:bcr-2018-224221.
7. Kang, D. J. et al. Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition. Clin. Transl. Gastroenterol. 7, e187 (2016).
8. Sartor, R. B. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment. Pharmacol. Ther. 43(Suppl. 1), 27–36 (2016).
9. Posserud, I., Stotzer, P. O., Björnsson, E. S., Abrahamsson, H. & Simrén, M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56, 802–808 (2007).